ArticleOTO open
Impact of Cisplatin on Hearing: Analysis Using PTA, High-Frequency Audiometry, DPOAE, and Speech-in-Noise Test.
Article in OTO open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.Drug delivery · 2026Pooled it
- Pre-treatment audiological and vestibular assessment in adults starting platinum-based chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess hearing loss in patients with cancer receiving cisplatin-based chemotherapy using high-frequency pure tone average (HFPTA), distortion product otoacoustic emissions (DPOAEs), and the speech-in-noise (SPIN) test, and to identify associated factors. Study Design: Prospective study. Setting: Tertiary care hospital. Methods: Patients scheduled for cisplatin chemotherapy were included in the study. Audiological assessments, including HFPTA, DPOAE, and SPIN tests, were conducted at baseline, after two cycles, and after four cycles of chemotherapy. Clinical data were also analyzed. Results: One-third of the population was aged between 51 and 60 years. Higher cumulative doses of cisplatin were administered for bladder and head and neck cancers, reaching up to 3200 mg over four cycles. Most patients had normal hearing at baseline, but HFPTA detected significant hearing loss at various frequencies (8-20 kHz) over follow-ups. DPOAE showed increased negative emissions over time. A weak, negative correlation between cisplatin dose and extended high-frequency audiometry (maximum -0.311 at 18 kHz) and DPOAE (maximum -0.173 at 1500 Hz) was observed. The SPIN test suggested reduced SPIN performance with treatment progression. However, correlation with cisplatin doses was not statistically significant. Conclusion: The study underscores the importance of integrated audiological monitoring in detecting early ototoxicity in cisplatin-treated patients, emphasizing the need for periodic auditory assessments during chemotherapy. SPIN test is a simple tool offering significant potential for ototoxicity monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.